Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Sponsors
Fred Hutchinson Cancer Center, M.D. Anderson Cancer Center, Roswell Park Cancer Institute
Conditions
Adult Synovial SarcomaHLA-A*0201 Positive Cells PresentMyxoid/Round Cell LiposarcomaNY-ESO-1 Positive Tumor Cells PresentPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPlatinum-Sensitive Fallopian Tube Carcinoma
Phase 1
NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
WithdrawnNCT02059850
Start: 2014-07-31End: 2016-01-31Updated: 2016-02-03
NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy
CompletedNCT02319824
Start: 2015-01-31Updated: 2017-07-05
Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma
CompletedNCT03450122
Start: 2018-09-13End: 2022-12-06Updated: 2023-10-16
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
TerminatedNCT03691376
Start: 2019-03-08End: 2024-06-24Updated: 2024-09-19